T. Rowe Price Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
Other funds holding IONS
T. Rowe Price Investment Management's IONS Position: Q2 2026 in Review
T. Rowe Price Investment Management reduced its Ionis Pharmaceuticals (IONS) stake by 36% in Q2 2026, selling an estimated $166M and leaving 3,959,372 shares worth $314M. The position accounts for 0.21% of the portfolio, ranked #131.
T. Rowe Price Investment Management first reported a position in IONS in Q3 2022 and has held it in 16 quarters since. The position peaked at $861M in Q3 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.
- T. Rowe Price Investment Management held 3,959,372 shares of Ionis Pharmaceuticals worth $314M as of Q2 2026.
- T. Rowe Price Investment Management sold 2,199,655 Ionis Pharmaceuticals shares in Q2 2026, an estimated $166M.
- Ionis Pharmaceuticals made up 0.21% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #131 holding.
- T. Rowe Price Investment Management first reported a position in Ionis Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
- T. Rowe Price Investment Management's Ionis Pharmaceuticals position peaked at $861M in Q3 2025.
- 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.
Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.